Grifols' Talecris purchase hits snag; Antisense's trabedersen gets good Phase IIb news;

 @FierceBiotech: In bombshell, DOJ reverses stance on gene patents. Report | Follow @FierceBiotech

 @JohnCFierce: Glaxo inks $231M pact for Phase III Amicus drug. Another rare disease pact for the pharma giant. Article  | Follow @JohnCFierce

> The Federal Trade Commission will try to halt Grifols's $3.3 billion acquisition of Talecris Biotherapeutics Holdings. It's the second time the FTC has stopped a Talecris sale based on antitrust issues. Report

> German biopharmaceutical company Antisense Pharma has released results from its Phase IIb study of trabedersen on malignant brain tumors. The drug had a significant impact on two-year survival and response rates. Antisense release

> Zalicus received a $244,000 grant to continue developing its Phase II product candidate Synavive, a potential rheumatoid arthritis therapy. Zalicus release

> Hyperion Therapeutics' glycerol phenylbutyrate, a urea cycle disorder therapy, has met its primary endpoint in a Phase III study. The 4-week, 46 patient study was conducted in June 2009. Hyperion release

> Patients taking inhaled corticosteroids are at increased risk of developing Type 2 diabetes, and more so with higher doses. Release

And Finally... Illicit drugs' allure is no new news; an exhibit at London's Wellcome Collection looks back at the use, benefits and issues of hallucinogens, cannabis and even espresso coffee throughout history and culture. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.